Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

max health limited - amisulpride 200mg - tablet - 200 mg - active: amisulpride 200mg excipient: lactose monohydrate magnesium stearate methylcellulose microcrystalline cellulose sodium starch glycolate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 200 mg - tablet - excipient ingredients: sodium starch glycollate type a; microcrystalline cellulose; methylcellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Australie - anglais - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amisulpride -

Singapour - anglais - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - amisulpride - tablet - 200 mg - amisulpride 200 mg

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 100 mg - tablet - excipient ingredients: lactose monohydrate; sodium starch glycollate type a; magnesium stearate; methylcellulose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 400 mg - tablet, film coated - excipient ingredients: titanium dioxide; sodium starch glycollate type a; methylcellulose; magnesium stearate; macrogol 6000; microcrystalline cellulose; lactose monohydrate; purified talc; basic butylated methacrylate copolymer - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

gm pharma international pty ltd - amisulpride, quantity: 50 mg - tablet - excipient ingredients: microcrystalline cellulose; lactose monohydrate; sodium starch glycollate type a; methylcellulose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; hypromellose; magnesium stearate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Jordanie - anglais - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة ألفه للأدوية - ulfa pharma co. - amisulpride 200 mg - 200 mg